Celgene, Taikang and WuXi AppTec have all taken part in a series B round for Antengene, which is working on treatments for cancers with a focus on Southeast and East Asia.
China-based oncology drug developer Antengene closed a $120m series B round backed by insurance company Taikang and pharmaceutical firms Celgene and WuXi AppTec yesterday.
Private equity firms Boyu Capital and FountainVest Partners co-led the round, while Qiming Venture Partners and TF Capital also contributed funding. WuXi AppTec invested through corporate venturing vehicle WuXi Corporate Venture Fund.
Antengene is developing cancer therapies with a focus on those with a high unmet medical need in China and the Asia Pacific region.
The company…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
